There’s a lot of interest in moving data to the cloud for security, centralization, and collaboration. Doing so, however, has implications for data integrity and audits. To understand more, we spoke to Monica Cahilly, the president and founder of Green Mountain Quality Assurance, in a podcast interview. Cahilly has more than 25 years of consulting experience, with specialized interest and enthusiasm for data integrity assurance and data governance. A short excerpt of that interview is presented here.
Monica Cahilly: The cloud is an exciting area. It helps lower cost, for example, for smaller organizations. Although it is an exciting area, I think what we have to be mindful of is that the cloud, in some instances, still poses some significant risks. I think we have to really understand the implications of moving into that environment, and then make sure that an audit team knows what those implications are, so that they can correctly qualify these environments, and then continuously monitor them at an appropriate frequency.
Cloud providers are, in fact, performing GXP-regulated work. What’s important for us to recognize is that these vendors may be inspected by authorities under certain circumstances, such as when a significant problem occurs in their GXP work that may impact patient safety, product quality, or the integrity of critical data. If there’s a problem that occurs because of something that is done by a vendor or one of their employees, then we obviously would be accountable for that as the contract giver. So we really have to understand that this is a contract acceptor–contract giver relationship and requires that the partnership be an active one. And we have to ensure that we are, in fact, doing adequate data monitoring.
When we think about 21 CFR Part 11, we have to remember that it was written back in the 1990s, well before these cloud environments became what they all are now, I think there was already some early virtualization of them back in that timeframe, but it has grown so much since then. Now we’ve got many cloud opportunities.
In 21 CFR Part 11 it say that when you place your data in the hands of a third party, you have additional risk. So, in the context of Part 11, that system would be referred to as an open system as opposed to a closed system (one where you’re managing your data under your own governance structure within your company). So, if the third party is a cloud provider, that is, in fact, an open system.
The text of 21 CFR Part 11 is not explicit on what to do with regard to open systems in a cloud environment. There are some suggestions; for example, we can encrypt the data in transit. We also might consider encrypting the data if we have confidentiality, security, data privacy, and intellectual property concerns that we need to be mindful about. As a result, we have to remember that we have additional risks in these environments. The audit team also needs to understand what those risks are and how to manage them. It is not just about quality systems and verifying that the cloud provider has a documented quality system framework that they follow, but it also requires that we include a cybersecurity specialist on our audits so that a designated person can assess how the cloud provider is managing the more challenging aspects of the current risks and the cybersecurity. This also requires that we institute data monitoring and data analytics.
One of the things that I think is important to remember is that in a cloud environment, on the user side, you are typically only going to be able to see the audit trails that are visible through the front end, if this is a software as a service. But even though you are only going to be able to see the audit trails that are visible to that front-end or application environment, you are also responsible for any activities that are taking place in the back-end environments. For example, in infrastructure environments that may have an impact on the integrity of our data that’s within that system, we may not be able to see those logs through the front end. How then do we get at that information so that we can really govern the risks that are potentially coming to bear on the data in these platforms? There are a lot of risks that we want to be mindful of, and we want to try to make sure that we do not move into these environments until we have a proper governance program in place for those risks. However, I think that if we have a proper governance program in place, and a really good data analytics, data monitoring, and data governance team, the opportunities available through the cloud are really exciting.
This interview has been lightly edited for style and space.
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ion used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.